Business Wire

LIXIL-JS-FOUNDATION

27.7.2016 07:14:00 CEST | Business Wire | Press release

Share
"The 6th LIXIL International Student Architectural Competition" Seeking and Reviewing Next-generation Sustainable Housing Technology; "INFINITE FIELD" by Royal Danish Academy of Fine Arts (Denmark) Wins Top Prize

The LIXIL JS Foundation (located in Koto-ku, Tokyo; Chairperson: Yoko Ushioda), which facilitates surveys and research related to the housing and building materials industries as well as supporting the development of human resources, conducted the Open Final Screening for the 6th LIXIL International Student Architectural Competition at the Keidanren Kaikan (Chiyoda-ku, Tokyo) on July 20, 2016 (Wed). The purpose of the competition is to seek and review next-generation sustainable housing technology and communicate that technology to the global society. The top three universities chosen from twelve participating universities in ten countries gave presentations, and INFINITE FIELD by Royal Danish Academy of Fine Arts (Denmark) was selected as the winner.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160726006668/en/

During the Open Final Screening, a heated discussion occurred between the head of jury, Kengo Kuma (Architect/ Professor, the University of Tokyo) and jurors, Tomonari Yashiro (Professor, Institute of Industrial Science, the University of Tokyo/ Vice President, the University of Tokyo), Masato Araya (Structural Designer/ Professor Emeritus, Waseda University), Yoshiharu Tsukamoto (Architect/ Co-founder of Atelier Bow-Wow/ Professor, Graduate school of Tokyo Institute of Technology) and Dana Buntrock (Architect, Department of Architecture, University of California, Berkeley). The theme of the 6th competition was “Comfort and Lightness.” As the competition’s first attempt, the contestants proposed a light shelter, which can be easily assembled and moved. This time around, as another first attempt, their mockups were actually brought in and exhibited at the hall for the final screening.

Royal Danish Academy of Fine Arts’ INFINITE FIELD was highly rated in various aspects, including a whole new architectural approach that can safely be referred to as an extension of “furniture” that gives consideration even to the form created by the human body and wood, a high degree of perfection of details, including materials to be cut and assembled, and a 360 degree open design that can become a big appeal when installed in Taiki-cho, Hokkaido.

In his general comments, the head juror, Kengo Kuma said, “Screening by using mockups was something innovative that I had never experienced and it gave the students a good opportunity to think about architecture starting with materials. Moreover, this competition was valuable also from a perspective of architectural culture in that their work remains.” At the award ceremony, Mr. Konstatinos Fetsis of Royal Danish Academy of Fine Arts commented, “I am very pleased to have been able to take part in this competition and this journey with these members. This has become such a wonderful experience that I will never forget as a student who majors in architecture.”

With support from Kengo Kuma & Associates, the team will arrive at a final design for “INFINITE FIELD,” and the project is scheduled to be built in October 2016 on a site at Memu Meadows, located in Taiki-cho, Hokkaido.

[Reference Information]
List of Winning Works
- Top Prize 
INFINITE FIELD by Royal Danish Academy of Fine Arts

- Award of Excellence (2 works)
LEVITATING ATMOSPHERES by HESAM University / ENSA Paris-La-Villette
Light Skin HOUSE by Yokohama National University

6th LIXIL International Student Architectural Competition
Theme: Comfort and Lightness
The contemporary concept of comfort hinges on blocking out the environment and creating barriers. But perhaps what we really need today is to live in closer proximity to nature. Please design a light shelter, one which can be easily assembled and moved, and also allows residents to enjoy a comfortable life. The ability to move the house means interpreting, considering, and creating a relationship with its surroundings. And the ability to easily assemble means it can become linked with the natural environment and ground, and draw out the richness of the place. Please devise a house that can be easily assembled and moved, and will allow the residents to enjoy the environment, both the summer and winter in Taiki-cho, Hokkaido. The relationship with nature and the surrounding area in your proposal might also include a method of interpreting the environment if the house was relocated to a city.

1. Participating universities: 12 universities in 10 countries
* The three universities marked with X proceeded to the Open Final Screening held on July 20, 2016.

  Cornell University (USA)
Parsons School of Design (USA)
Universidad Nacional Autónoma de México (México)

X

Royal Danish Academy of Fine Arts (Denmark)

Polytechnic of Milan (Italy)

X

HESAM University / ENSA Paris-La-Villette (France)

Swiss Federal Institute of Technology (ETH) Zurich (Switzerland)
University of Melbourne (Australia)
Chulalongkorn University (Thailand)
University of Cape Town (South Africa)
Kyoto Institute of Technology (Japan)

X

Yokohama National University (Japan)

 

2. Judging method
Twelve universities in ten countries were invited to submit proposals for a next-generation, sustainable house designed for a cold region. Three entrants were then selected in the first screening (based on documents submitted). The top prize winner was subsequently chosen in the Open Final Screening.

3. Jury:
Kengo Kuma (Professor at the Graduate School of Architecture, The University of Tokyo)
Tomonari Yashiro (Deputy Director and Professor at the Institute of Industrial Science, The University of Tokyo)
Masato Araya (Structural Engineer, Professor Emeritus at Waseda University)
Yoshiharu Tsukamoto (Professor at Tokyo Institute of Technology, Co-Principal of Atelier Bow-Wow)
Dana Buntrock (Professor at Department of Architecture, University of California, Berkeley)

4. Prizes
Top prize (one work): $15,000 (USD; including design fee)
Award of Excellence (two works): $3,000

*The winner’s work “INFINITE FIELD” will be built on a site at Memu Meadows, located in Taiki-cho, Hokkaido (to be completed in October 2016).

Contact:

LIXIL JS Foundation
Kumeo Takahata, +81(0)3-5626-1008
2-1-1, Oshima, Koto-ku, Tokyo 136-8535
LIXIL JS Foundation website: http://www.lixiljsfound.com/

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye